Animal Models of Depression - Chronic Despair Model (CDM)
September 23rd, 2021
The chronic despair mouse model (CDM) of depression consists of repetitive forced swim sessions and another delayed swim phase as a read-out. It represents a suitable model for induction of a chronic depressive-like state stable for at least 4 weeks, amendable to evaluate subchronic and acute treatment interventions.
The chronic despair model represents a suitable model for the induction of a chronic depressive-like state in mice in order to better understand the path of physiology of mood disorders and to evaluate potential antidepressive treatment interventions. Repetitive stress is used to induce a depressive-like state, following the idea that in humans depression is induced by chronic rather than acute stress. Since the effects of CDM induction are stable for up to four weeks, it is not only possible to investigate rapid acting antidepressants, but also substances with a delayed onset like most conventional antidepressants.
Before inducing the chronic depressive-like state, visually observe the mice for abnormalities including signs of biting or barbering. Exclude the whole cage from the experimental series if an animal shows signs of injury. To perform paired parametric tests afterward, make sure that each mouse is clearly marked or labeled.
Additionally weigh each mouse before starting the experiment. To perform a forced swim session, fill up a beaker or cylinder with room temperature water to a height of at least 20 centimeters from the bottom, leaving a minimum of 10 centimeters between the water surface and the upper border of the vessel. Then gently transfer the mouse into the water and set a timer for 10 minutes.
To prevent the mouse from drowning, continuously observe the mouse while it is in the water from a position where it cannot see the experimenter. After 10 minutes, take the mouse out of the water by simply grabbing its tail. Gently dry the mouse with a paper towel, and put it either under a heating light or on a heating mat.
Perform the forced swim session on each mouse every day for five consecutive days. After five swim sessions, transfer the animals back to their home cages and allow them to rest for at least two days. To use immobility time as read out method, record each swim session using a camera.
Then watch the offline video recordings and use a stopwatch to measure the total time spent by the mouse in the three different behavioral conditions during the swim test, struggling, swimming and immobility. The animal is considered to be struggling when it actively tries to escape from the threatening situation. This involves pawing the side of the cylinder with head oriented toward the wall and moving all limbs.
The water surface is typically slightly turbulent. The animal is considered to be swimming when it moves at least both hide paws and travels a distance through the water. It actively searches for a way out but does not lift its paws above the water surface or try to overcome the glass wall of the vessel.
In this condition animals frequently turn around or move in circles. Lastly, the animal is considered to be in the immobility stage. If it keeps still in a freezing-like position and does not move at all, or only moves the tail, or the forepaws to keep its head above the water surface, no distance is actively traveled except for passive floating, and no directed movement of the front paws is observed.
In the induction phase of the chronic despair model, during the first swim session, mice usually show a mean immobility time between 190 and 230 seconds, which then constantly increases with every additional swim session. The immobility time measured on day five remains stable over four weeks indicating stable behavioral despair. Antidepressive interventions, such as imipramine, sleep deprivation and ketamine, significantly reduce the immobility time.
While sleep deprivation combined with a recovery sleep does not show a significant change of the depressive-like phenotype. Since each treatment group has different mean values of immobility time on day five, different treatments should be compared using normalized mean values instead of absolute values. If immobility time remains unchanged during all five days, the applied stress could not change the behavior relevantly, and thus these mice cannot be used to evaluate treatment effects.
Other readout methods such as tail suspension test, nose poke sucrose preference test, and assessment of long term potentiation during the patch clamp technique can be used to describe a broader view of the behavioral despair of the animals. Measurement of the immobility time is an important part of the chronic despair model, but it should never be the only readout method. Multiple other assessments like the tail suspension test or sucrose preference test should be used.
View the full transcript and gain access to thousands of scientific videos
Overview
The chronic despair mouse model (CDM) is utilized to induce a stable chronic depressive-like state in mice, lasting at least four weeks. This model aids in understanding mood disorders and evaluating potential antidepressant treatments.
Key Study Components
Area of Science
- Neuroscience
- Behavioral Science
- Psychopharmacology
Background
- The CDM mimics the chronic stress that can lead to depression in humans.
- Repetitive stress is applied to induce depressive-like symptoms in mice.
- Stability of the depressive state allows for testing both rapid and delayed onset antidepressants.
- Monitoring for animal welfare is crucial before and during the study.
Purpose of Study
- To investigate the physiological mechanisms underlying mood disorders.
- To evaluate the efficacy of various antidepressant treatments.
- To provide a reliable model for future research in depression.
Methods Used
- Induction of chronic depressive-like state through forced swim sessions.
- Visual observation of mice for signs of injury or abnormal behavior.
- Exclusion of affected animals from the study to ensure welfare.
- Labeling of mice for accurate data collection in paired tests.
Main Results
- Establishment of a stable depressive-like state in mice.
- Ability to assess both immediate and delayed effects of antidepressants.
- Identification of behavioral changes indicative of depression.
- Insights into the physiological responses to chronic stress.
Conclusions
- The CDM is a valuable tool for studying depression and treatment responses.
- Findings contribute to understanding the impact of chronic stress on mood disorders.
- Future research can build on this model to explore new therapeutic avenues.
Frequently Asked Questions
Executive Industry Relevance
The Chronic Despair Model (CDM) addresses a critical gap in antidepressant discovery by modeling sustained behavioral despair induced by chronic stress, mirroring the delayed onset of clinical antidepressants. This enables mechanistic de-risking of target hypotheses and supports predictive confidence in lead identification for both rapid- and delayed-acting compounds. The model’s stability over four weeks provides a translational window for subchronic treatment strategies, improving portfolio triage and reducing late-stage biological risk in CNS drug development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses related to chronic stress pathophysiology and functional validation of targets implicated in sustained depressive-like states.
- Operational Value: Supports biological de-risking by stabilizing a despair phenotype for repeated testing across compound classes.
- Predictive Value: Facilitates portfolio prioritization by distinguishing compounds with transient effects from those producing sustained reduction in immobility, correlating with clinical antidepressant profiles.
Screening & Assay Development
- Assay Readiness: Generates a validated, reproducible biological system with quantifiable immobility endpoints suitable for high-throughput screening of antidepressant candidates.
- Quantitative Output: Immobility time measurement provides a continuous, scalable readout enabling dose-response analysis and inter-laboratory standardization.
- Multi-parametric Profiling: Integration with tail suspension, sucrose preference, and electrophysiological assays allows comprehensive mood status assessment beyond single-behavior readouts.
Translational & Preclinical Research
- Disease Relevance: Models chronic stress-induced depression, offering face and construct validity for studying treatment-resistant and delayed-onset antidepressant responses.
- Translational Continuity: The four-week stability of the depressive phenotype bridges acute discovery and chronic preclinical evaluation, supporting risk-adjusted advancement decisions.
- Mechanistic De-risking: Enables monitoring of molecular and electrophysiological changes alongside behavior, strengthening target engagement and pathway validation.
Pipeline & Workflow Integration
The CDM fits within the discovery continuum from target validation through lead identification to preclinical efficacy testing, particularly for antidepressants requiring chronic dosing regimens.
- Discovery Biology: Supports hypothesis testing on chronic stress mechanisms and pathway clarification via behavioral, molecular, and electrophysiological readouts.
- Screening: Enables assay standardization and reproducibility through quantified immobility time, facilitating reliable compound evaluation across chemotypes.
- Analytics: Provides quantitative behavioral measurements and normalized mean comparisons essential for statistical analysis and cross-group treatment comparisons.
- Translational Research: Connects early discovery to preclinical validation by maintaining a stable phenotype for subchronic treatment studies, aligning with clinical antidepressant timelines.
- Enterprise Reuse: Functions as a reusable platform for iterative screening, target validation, and mechanism-of-action studies across multiple antidepressant programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence by modeling chronic antidepressant response and reducing mechanistic ambiguity in mood disorder pathways.
- Operational Value: Delivers standardized, reproducible workflows with defined stress induction, rest periods, and quantified behavioral endpoints.
- Strategic Value: Improves go/no-go decisions by identifying compounds with sustained efficacy, reducing late-stage failure due to lack of chronic effect.
- Portfolio Impact: Enables risk-adjusted prioritization of antidepressants based on durability of response, supporting capital efficiency in CNS portfolios.
Implementation Considerations
- Requires expertise in rodent behavioral neuroscience, stress modeling, and antidepressant pharmacology.
- Dependent on controlled environmental infrastructure for swim sessions, video tracking, and behavioral scoring.
- Necessitates cross-team standardization of immobility scoring criteria and animal handling protocols to ensure data consistency.
- Involves adaptation considerations when extending to other species or stress paradigms, with validation needed for cross-model translatability.
- Limited by the need for exclusion of injured or abnormal animals, which may affect cohort size and requires pre-screening welfare checks.
